AzurRx BioPharma Announces First Two Patients Dosed in Phase 2b OPTION 2 Extension Study of MS1819 in Cystic Fibrosis Patients
January 21, 2021 at 01:00 pm
AzurRx BioPharma, Inc. announced the first two patients have been dosed in the Phase 2b OPTION 2 extension study of MS1819 using immediate release capsules for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis. The company recently announced an additional study arm in the Phase 2b OPTION 2 study utilizing immediate release capsules in efforts to identify the optimal dose and delivery method of MS1819. The OPTION 2 extension phase design will test patients 18 years or older, who have already completed the OPTION 2 crossover trial, at higher doses relative to the previously conducted OPTION 1 trial. As of now, two patients have been dosed and will continue to be treated for the duration of the next two weeks.